LEADER 00869nam a22002411i 4500 001 991004041469707536 005 20040714093832.0 008 040802s1952 it |||||||||||||||||ita 035 $ab13163401-39ule_inst 035 $aARCHE-111601$9ExL 040 $aBiblioteca Interfacoltà$bita$cA.t.i. Arché s.c.r.l. Pandora Sicilia s.r.l. 082 04$a853.7 100 1 $aMarino, Domenico$089461 245 10$aPane azzimo /$cDomenico Marino 260 $aRoma :$bA. Signorelli,$cstampa 1952 300 $a81 p. ;$c21 cm 700 1 $aStefanile, Mario 907 $a.b13163401$b02-04-14$c05-08-04 912 $a991004041469707536 945 $aLE002 Fondo Giudici Busta 9/006$g1$i2002000741004$lle002$nC. 1$o-$pE0.00$q-$rn$so $t0$u0$v0$w0$x0$y.i13802732$z05-08-04 996 $aPane azzimo$9311691 997 $aUNISALENTO 998 $ale002$b05-08-04$cm$da $e-$fita$git $h0$i1 LEADER 04740nam 2201369z- 450 001 9910637778703321 005 20221206 010 $a3-0365-5955-8 035 $a(CKB)5470000001631752 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/94560 035 $a(oapen)doab94560 035 $a(EXLCZ)995470000001631752 100 $a20202212d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aPlant Therapeutics 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 online resource (280 p.) 311 08$a3-0365-5956-6 330 $aThis Special Issue provides recent advances in the use of plants for therapeutic purposes. This Special Issue collected the plants, including leaf, fruit, and others. This Special Issue's targets were crude plant extract and active principle purified from the plant. This Special Issue prompted researchers to provide each plant discovery. We are pleased to include in this Special Issue the screened Mexican plants and the halophytic plants growing in central Saudi Arabia, and so on. As a result, we have sparked scientists' interest in studying the plant for therapeutic purposes. This field necessitates network pharmacology analysis and machine-aided learning. Many disorders resistant to modern medication are looking for active principles isolated from the plants all over the world. 606 $aMedicine and Nursing$2bicssc 606 $aPharmacology$2bicssc 610 $aAcalypha arvensis 610 $aAcalypha monostachya 610 $aaged rat 610 $aAlsophila firma 610 $aAlzheimer's disease 610 $aamyloid ? 610 $aAnabasis articulata 610 $aanti-aging 610 $aanti-cancer 610 $aanti-inflammatory 610 $aantibacterial 610 $aanticancer 610 $aantimicrobial 610 $aantioxidant 610 $aantioxidant potential 610 $aapolipoprotein E-deficient mice 610 $aatherosclerosis 610 $abilberry juice 610 $abioactive derivative 610 $abiogenetic interrelationship 610 $ablack bean soybean sauce 610 $abrain-derived neurotrophic factor 610 $aby-product 610 $acorilagin 610 $acytotoxic effect 610 $adepression 610 $adiabetes 610 $aDrosophila melanogaster 610 $aellagitannin 610 $aendothelium 610 $aEryngium longifolium 610 $aextractor Naviglio® 610 $afast dissolving films 610 $afibrosis 610 $aflavonoid 610 $aflavonoid contents 610 $aflavonoids 610 $afructose 1,6-bisphosphatase 610 $afunctional supplements 610 $aGan-Mai-Da-Zao 610 $aGC-MS 610 $aglucose 6-phosphatase 610 $aherbal medicine 610 $ahigh-fat diet 610 $aHPLC-PDA 610 $ahuman tumor cell lines 610 $ahydroxysafflor yellow A 610 $ahypoglycemic plants 610 $aimmunomagnetic reduction 610 $ainflammation 610 $aInga jinicuil 610 $ainsulin secretion 610 $akidney disease 610 $aLindera obtusiloba 610 $aLycium shawii 610 $amedium pressure liquid chromatography (MPLC) 610 $amethylglyoxal 610 $aMoringa oleifera 610 $an/a 610 $anon-alcoholic fatty liver disease 610 $aphytochemical profile 610 $aplant extracts 610 $aplatelet aggregation 610 $arapid solid-liquid dynamic extraction (RSLDE) 610 $aRumex vesicarius 610 $asafflower 610 $asafflower yellow A 610 $aSalvia haematodes 610 $aserotonin transporter 610 $aSoxhlet apparatus 610 $aStaphylococcus aureus 610 $atrace elements 610 $atraditional medicine 610 $atriple negative breast cancer 610 $aunpredictable chronic mild stress 610 $avescalagin 610 $awater extract of fermented rice bran 610 $aWnt/?-catenin 610 $ayeast ?-glucan 610 $aZilla spinosa 615 7$aMedicine and Nursing 615 7$aPharmacology 700 $aCheng$b Juei-Tang$4edt$01285496 702 $aLiu$b I-Min$4edt 702 $aShen$b Szu-Chuan$4edt 702 $aCheng$b Juei-Tang$4oth 702 $aLiu$b I-Min$4oth 702 $aShen$b Szu-Chuan$4oth 906 $aBOOK 912 $a9910637778703321 996 $aPlant Therapeutics$93019607 997 $aUNINA LEADER 05130nam 2201237z- 450 001 9910595078103321 005 20220916 035 $a(CKB)5680000000080745 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/92020 035 $a(oapen)doab92020 035 $a(EXLCZ)995680000000080745 100 $a20202209d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aPrecision Medicine in Solid Tumors 210 $aBasel$d2022 215 $a1 online resource (304 p.) 311 08$a3-0365-4791-6 311 08$a3-0365-4792-4 330 $aIn the era of precision medicine, the use of molecularly targeted therapies in selected patients has led to a paradigm change in cancer treatment. Multiple studies have demonstrated the benefits of therapies that are chosen based on the molecular profile of the tumor and also from the liquid biopsy. With genomics' increasing ability, a routine transcriptomics analysis of advanced/metastatic cancers is now feasible in most cancer hospitals, including community cancer centers. This is an unprecedented shift in the management of cancers irrespective of their organ types, which not only improved the outcome but also opened several new avenues in research and practice, such as immune-check-point inhibitors, tumor-TME co-evolution in the development of resistance, longitudinal liquid biopsies, biomarkers screening and the management of electronic medical records.This book brings together these crucial areas of investigation. The research presented here attempts to address the current issues to provoke thoughts for the future. The future of precision medicine will have to embrace a shift from in vitro, in vivo/PDX models for the mechanistic study to a more functional test based on the scientific interrogation of genomic data, in the form of functional precision medicine. We will also have to combat the element of noise in the multitudes of data and impart the regulatory structure to make judicious use of the data. The expectations for functional precision medicine are high. We aspire to witness a tremendous improvement in patient outcomes, from better to best, down the road that will match the clinical guidelines. 606 $aMedicine and Nursing$2bicssc 606 $aOncology$2bicssc 610 $aadjuvant chemotherapy 610 $aanaplastic lymphoma receptor tyrosine kinase 610 $abreast cancer 610 $acancer 610 $acancer-associated fibroblasts 610 $acfDNA 610 $achemotherapy 610 $acirculating free DNA 610 $aclinical guideline 610 $aclonality classification 610 $acomprehensive genomic profiling 610 $aCTC 610 $actDNA 610 $aDDR genes 610 $aDecision tree 610 $adigital enrichment 610 $adriver mutation 610 $aEGFR mutation 610 $aEGFR-TKI 610 $aelectronic records 610 $aepidermal growth factor receptor 610 $aextent of resection 610 $agene panel sequencing 610 $aglioblastoma prognosis 610 $aHNSCC 610 $aimmune checkpoint inhibitors 610 $aimmunocytochemistry 610 $aimmunotherapy 610 $aintratumor heterogeneity 610 $alaboratory-friendly 610 $aliquid biopsy 610 $amolecular barcoding 610 $amolecular genotyping 610 $amultiple biopsies 610 $an/a 610 $anew drug development 610 $anext-generation sequencing 610 $anext-generation sequencing (NGS) 610 $aNGS 610 $anon-small cell lung cancer 610 $aopen data 610 $aosimertinib 610 $aoutcome 610 $aoverall survival 610 $aparallel double-detection 610 $aPARP inhibitors 610 $aPD-L1 610 $apediatric tumors 610 $apersonalized precision oncology 610 $aprecision medicine 610 $apresumed germline findings 610 $arandom forest 610 $aregulatory reform 610 $aresistance 610 $ascreening 610 $asequencing 610 $asmoking 610 $asolid cancer 610 $astrategic therapeutic intervention 610 $atargeted therapy 610 $atDNA 610 $athymoma 610 $aTMB 610 $aTNBC subtypes 610 $atriple-negative breast cancer (TNBC) 610 $atumor evolution 610 $atumor mutational burden 610 $atumor profiling test 610 $atyrosine kinase inhibitor 610 $auniversal health-care system 610 $awhole-exome sequencing 615 7$aMedicine and Nursing 615 7$aOncology 700 $aDey$b Nandini$4edt$01332329 702 $aDe$b Pradip$4edt 702 $aDey$b Nandini$4oth 702 $aDe$b Pradip$4oth 906 $aBOOK 912 $a9910595078103321 996 $aPrecision Medicine in Solid Tumors$93040843 997 $aUNINA